Literature DB >> 25817049

Treatment of Langerhans cell histiocytosis: it is time to learn from the past: response to Minkov and Rodriguez-Galindo.

Carl E Allen1,2, Kenneth L McClain3,4.   

Abstract

Entities:  

Keywords:  Langerhans cell histiocytosis; cytarabine; prednisone; vinblastine

Mesh：

Year:  2015        PMID： 25817049      PMCID： PMC4573766          DOI： 10.1111/bjh.13371

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  7 in total

1.  High prevalence of somatic MAP2K1 mutations in BRAF V600E-negative Langerhans cell histiocytosis.

Authors:  Noah A Brown; Larissa V Furtado; Bryan L Betz; Mark J Kiel; Helmut C Weigelin; Megan S Lim; Kojo S J Elenitoba-Johnson
Journal:  Blood       Date:  2014-06-30       Impact factor: 22.113

2.  Up-front therapy for LCH: is it time to test an alternative to vinblastine/prednisone?

Authors:  Stephen J Simko; Kenneth L McClain; Carl E Allen
Journal:  Br J Haematol       Date:  2014-11-16       Impact factor: 6.998

3.  Recurrent BRAF mutations in Langerhans cell histiocytosis.

Authors:  Gayane Badalian-Very; Jo-Anne Vergilio; Barbara A Degar; Laura E MacConaill; Barbara Brandner; Monica L Calicchio; Frank C Kuo; Azra H Ligon; Kristen E Stevenson; Sarah M Kehoe; Levi A Garraway; William C Hahn; Matthew Meyerson; Mark D Fleming; Barrett J Rollins
Journal:  Blood       Date:  2010-06-02       Impact factor: 22.113

4.  Therapy prolongation improves outcome in multisystem Langerhans cell histiocytosis.

Authors:  Helmut Gadner; Milen Minkov; Nicole Grois; Ulrike Pötschger; Elfriede Thiem; Maurizio Aricò; Itziar Astigarraga; Jorge Braier; Jean Donadieu; Jan-Inge Henter; Gritta Janka-Schaub; Kenneth L McClain; Sheila Weitzman; Kevin Windebank; Stephan Ladisch
Journal:  Blood       Date:  2013-04-15       Impact factor: 22.113

5.  Mutually exclusive recurrent somatic mutations in MAP2K1 and BRAF support a central role for ERK activation in LCH pathogenesis.

Authors:  Rikhia Chakraborty; Oliver A Hampton; Xiaoyun Shen; Stephen J Simko; Albert Shih; Harshal Abhyankar; Karen Phaik Har Lim; Kyle R Covington; Lisa Trevino; Ninad Dewal; Donna M Muzny; Harshavardhan Doddapaneni; Jianhong Hu; Linghua Wang; Philip J Lupo; M John Hicks; Diana L Bonilla; Karen C Dwyer; Marie-Luise Berres; Poulikos I Poulikakos; Miriam Merad; Kenneth L McClain; David A Wheeler; Carl E Allen; D Williams Parsons
Journal:  Blood       Date:  2014-09-08       Impact factor: 22.113

6.  Permanent consequences in Langerhans cell histiocytosis patients: a pilot study from the Histiocyte Society-Late Effects Study Group.

Authors:  Riccardo Haupt; Vasanta Nanduri; Maria Grazia Calevo; Cecilia Bernstrand; Jorge L Braier; Valerie Broadbent; Guadalupe Rey; Kenneth L McClain; Gritta Janka-Schaub; R Maarten Egeler
Journal:  Pediatr Blood Cancer       Date:  2004-05       Impact factor: 3.167

7.  BRAF-V600E expression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groups.

Authors:  Marie-Luise Berres; Karen Phaik Har Lim; Tricia Peters; Jeremy Price; Hitoshi Takizawa; Hélène Salmon; Juliana Idoyaga; Albert Ruzo; Philip J Lupo; M John Hicks; Albert Shih; Stephen J Simko; Harshal Abhyankar; Rikhia Chakraborty; Marylene Leboeuf; Monique Beltrão; Sérgio A Lira; Kenneth M Heym; Venetia Bigley; Matthew Collin; Markus G Manz; Kenneth McClain; Miriam Merad; Carl E Allen
Journal:  J Exp Med       Date:  2014-03-17       Impact factor: 14.307
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.